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I
n the past 15 years, multiple clinical
trials have attempted to ﬁnd preven-
tion for type 1 diabetes. The accompa-
nying article by Bresson and von Herrath
(1) reviews basic mechanisms underlying
immunoprevention and immunotherapy
of type 1 diabetes as well as selected hu-
man trials in the context of data from an-
imalmodels.Thesecondpartofthismini-
symposium provides an overview of the
recentorongoinghumantrials.Immuno-
therapy for prevention of type 1 diabetes
or to ameliorate the course of the disease
after clinical diagnosis is currently re-
strictedtoresearchstudies.Referencesare
provided to the clinical.trials.gov data-
base or other sources where the reader
can ﬁnd additional information.
Type 1 diabetes is an autoimmune
disease caused by interplay of genetic and
environmental factors. Figure 1 summa-
rizes the main stages in the development
of type 1 diabetes and examples of pre-
vention trials at these stages. The initial
step—development of islet autoimmu-
nity marked by the presence of autoanti-
bodies to insulin, GAD (GAD65),
insulinoma-associated protein 2 (IA-2),
and tyrosine phosphatase or zinc trans-
porter (ZnT8)—is believed to be driven
by environmental trigger(s) (2). Over the
past 40 years, the incidence of childhood
type 1 diabetes worldwide has increased
by 3–5% annually (3–6). Elimination of
the environmental trigger(s) responsible
for this epidemic would be the most efﬁ-
cient approach to primary prevention.
However, there is lack of consensus re-
garding which environmental factor(s)
initiatesisletautoimmunity.TheNational
Institutes of Health have established The
Environmental Determinants of type 1
Diabetes in the Young (TEDDY) consor-
tium to evaluate the leading candidates
(7,8).
After initiation of islet autoimmunity,
most patients have a long preclinical pe-
riod (9–12) that offers opportunity for
secondary prevention—halting progres-
sion to clinical diabetes (Fig. 1). Large
randomized trials initiated in the 1990s,
including the Diabetes Prevention Trial
Type 1 (DPT-1), the European Nicotin-
amide Diabetes Intervention Trial
(ENDIT),andtheDiabetesPredictionand
Prevention (DIPP) project (13–16), have
targeted this stage of pre–type 1 diabetes.
The trials (17,18) and a cohort study (19)
have shown that mild asymptomatic hy-
perglycemia, detected by oral glucose tol-
erance test (OGTT) or A1C, may precede
by months or years overt insulin depen-
dence among individuals with islet auto-
antibodies. Intervention at this
“dysglycemic” stage of pre–type 1 diabe-
tes may theoretically preserve endoge-
nous insulin secretion and prevent acute
and long-term complications of type 1 di-
abetes (20–22).
For the same reasons, preservation or
restoration of insulin secretion after diag-
nosisofdiabetescontinuestobeanattrac-
tive goal. Such tertiary prevention trials
have used a number of immunomodula-
tory agents. These agents are often con-
sidered ﬁrst in patients with established
diabetes and, when proven safe, may be
appliedtopatientswithdysglycemicpre–
type 1 diabetes and eventually those with
normoglycemic pre–type 1 diabetes.
However, efﬁcacy in preserving C-
peptide after diagnosis of type 1 diabetes
should not be a precondition to applying
an intervention to patients with pre–type
1 diabetes, as there may be a “point of no
return” in the autoimmune destruction of
the islets, rendering some interventions
effective only at the earlier stages of the
process.
Current approaches to prevent type 1
diabetes include:
● Avoidance of environmental triggers
of islet autoimmunity such as cow’s
milk or gluten. Celiac disease pro-
vides an encouraging example of au-
toimmune disease that can be pre-
vented in this way. Alternatively, diet
is supplemented with nutrients for
whichdeﬁciencypresumablypromotes
islet autoimmunity, e.g., n-3 fatty acids
or vitamin D.
● Antigen-speciﬁc “vaccination” using is-
let autoantigens, e.g., intact insulin, al-
tered insulin or proinsulin peptides,
GAD65, or heat shock protein 60
(HSP60) peptide. The goal is to induce
autoantigen-speciﬁc tolerance by in-
duction of regulatory T-cells that
downregulate immunity to a speciﬁc
autoantigen as well as promote toler-
ance to additional autoantigens.
● Non–antigen-speciﬁc systemic thera-
pies that range from mild modulation
with oral nicotinamide or bacille
Calmette–Guerin (BCG) vaccination to
immunosuppression and cellular
therapies.
● Stimulation of -cell regeneration in
conjunction with suppression of apo-
ptosis that is increased in islet autoim-
munity to overcome the relapsing-
remitting course of pre-diabetes.
● Metabolic modiﬁcations, such as
weightlossandmaintenance,increased
physical activity, and -cell rest.
PRIMARY PREVENTION OF
ISLET AUTOIMMUNITY— The
target population for primary prevention
trials are young children who carry high-
risk HLA-DR,DQ genotypes. Finding
such children in the general population is
hampered by low speciﬁcity of these ge-
notypes; the speciﬁcity is much higher in
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type 1 diabetes, i.e., ﬁrst-degree relatives.
While a number of non-HLA susceptibil-
itygenemarkershavebeenreported,they
have yet to be included in the design of
primary prevention trials. The young age
of potential trial participants and that
most of them will never develop diabetes
sets the safety bar high for prevention tri-
als in this population. Ongoing primary
prevention trials, summarized in Table 1,
include largely low-risk dietary modiﬁca-
tions: elimination of cow’s milk (23) or
gluten (24) and supplementation of diet
with n-3 fatty acids (25) or vitamin D. A
pilot trial of antigen-speciﬁc immuno-
modulation is using insulin (26) found
previously to be safe in large secondary
prevention trials.
Dietary modiﬁcations
The cow’s milk hypothesis is being tested
by the Trial to Reduce type 1 diabetes in
theGeneticallyatRisk(TRIGR)(23).This
randomized, double-masked trial is eval-
uating the effect of hydrolyzed infant for-
mula, where protein fragments are too
small to stimulate the immune system,
compared with cow’s milk–based for-
mula. Eligible to participate were new-
borns who had a ﬁrst-degree relative with
type 1 diabetes and one of the high-risk
HLA-DQ genotypes. The recruitment of
2,160 children from 77 centers in 15
countries was completed at the end of
2006. All participant mothers received
the recommendation to breast-feed for at
least the ﬁrst 6 months of life. If a mother
was unable to exclusively breast-feed be-
fore the baby was 8 months of age, her
child was randomly assigned to either a
formulaofextensivelyhydrolyzedprotein
(Nutramigen) or a formula based on non-
hydrolyzedcow’smilk(Enfamil)contain-
ing a small amount of Nutramigen (for
masking purpose).The main end point of
the trial is development of diabetes by the
age of 10 years.
The Finnish Intervention Trial for the
Prevention of Type I Diabetes (FINDIA)
tests an extension of the cow’s milk hy-
pothesis, i.e., that bovine insulin present
in cow’s milk triggers islet autoimmunity.
FINDIA includes two arms similar to
TRIGR, and, in addition, one-third of
high-risk infants receive insulin-free
whey-based formula. In contrast to
TRIGR, none of the 982 high-risk chil-
dren participating in FINDIA has a ﬁrst-
degree relative with type 1 diabetes
(O.Vaarala, unpublished data). The in-
terim results of the 3-year follow-up of
study participants is expected in early
2009.
BABY DIET is another example of an
elimination diet trial (24). This random-
ized, unmasked feasibility study is evalu-
ating the effect of delaying exposure to
gluten until the age of 1 year.
The TrialNet Nutritional Interven-
tion to Prevent type 1 diabetes (NIP)
(27) is a pilot study that enrolled preg-
nant women in their 3rd trimester ex-
pecting high-risk babies based on
family history. In addition, newborn
ﬁrst-degree relatives with high-risk
HLA-DR,DQ genotypes were enrolled.
The trial was not powered to formally
test efﬁcacy of dietary supplementation
with docosahexaenoic acid (DHA) be-
fore 6 months of age but rather to pilot
the feasibility of a deﬁnitive trial.
Vitamin D supplementation in early
childhood has attracted attention as a
possible primary preventive measure
(28,29). However, this interest has been
mitigated by potential nephrotoxicity of
vitamin D (30). At least one phase I clin-
ical trial is testing the feasibility of this
approach (31).
Antigen-speciﬁc vaccines
The Primary Oral/intranasal INsulin Trial
(POINT) investigators (26), encouraged
by the excellent safety proﬁle in second-
ary prevention trials of oral (15) and in-
tranasal insulin (16), have initiated a
feasibilitytrialofprimarypreventionwith
oral or intranasal insulin vaccination. The
pre-POINT phase I trial will determine
the dose and route of insulin administra-
tion that is safe and is bioavailable to the
immune system. The study will deter-
mine whether administration of insulin
leads to both B- and T-cell responses that
have characteristics consistent with pro-
tection. Protective B-cell responses may
potentially include production of IgA-
insulin antibodies, lower-afﬁnity insulin
antibodies, and insulin antibodies that do
not react with proinsulin. T-cell re-
sponses to insulin will be evaluated by
ELISpots, with increased production
Th2-type cytokines such as interleukin
(IL)-4, IL-10, and transforming growth
factor- suggesting protection. Eligible
are children who have multiple ﬁrst-
degree relatives with type 1 diabetes or
those who have the HLA-DR3/DR4-DQ8
genotype inherited identical by descent
withasiblingproband;suchsiblingshave
type 1 diabetes risk as high as 80% (32).
Children will be monitored for the devel-
opment of islet autoantibodies, diabetes,
and protective immune responses to in-
sulin. Depending upon the outcome of
pre-POINT,thestudywillcontinuetothe
phase II POINT study, which will deter-
mine the efﬁcacy of mucosal insulin ad-
ministration in primary prevention.
SECONDARY PREVENTION
OF CLINICAL DIABETES— Ap-
proximately 1 in 20 ﬁrst-degree relatives
and 1 in 300 people without type 1 dia-
betes in the immediate family has multi-
ple islet autoantibodies. That is, 1 million
people in the U.S. alone are currently at
an increased risk of developing type 1 di-
abetes. Most young individuals with mul-
tiple islet autoantibody positivity
progress to diabetes in 5–10 years; how-
ever, the rate of progression decreases
with age. Preventing insulin dependency
in a signiﬁcant proportion of this popula-
tion would be a major public health
achievement. However, it is expensive to
identify these high-risk subjects, about
Figure 1—Natural history of type 1 diabetes and prevention opportunities.
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DPT-1, and four large prevention trials
have found no effect on the rate of pro-
gression to clinical type 1 diabetes for in-
sulin administered parenterally (13),
orally (15), or intranasally (16), as well as
for oral nicotinamide (14). Smaller stud-
ies have evaluated other agents, also with
littlesuccess.Wewillnotreviewdetailsof
these studies, as they have been widely
publicized. Two large randomized dou-
ble-masked secondary prevention trials
using oral and intranasal insulin are still
underway (33,34) (Table 1). Interest-
ingly, a post hoc analysis of data from the
DPT-1 trial of oral insulin suggested that
relatives with high levels of insulin auto-
antibodiesappearedtoexperienceadelay
in progression to diabetes by 4 years
(15).Thisobservationledtoasecondoral
insulin trial, conducted by the Type 1 Di-
abetes TrialNet consortium. The study is
enrolling ﬁrst-degree relatives age 1–45
years and second-degree relatives age
1–20 years (the relative with diabetes
must have been diagnosed before the age
of 40 years and started on insulin within
the1styearofdiagnosis).Eligiblesubjects
must be positive for insulin autoantibod-
ies on two samples within a 6-month pe-
riod and meet additional criteria for other
isletautoantibodies.AsofFebruary2009,
an initial 121 of the anticipated 400 sub-
jects have been randomized.
TheDPT-1andENDITdatahavepro-
vided a wealth of information concerning
prediction of type 1 diabetes and trial de-
sign. In October 2001, the DPT-1 trial
centers and several new centers formed
the Type 1 Diabetes TrialNet consortium
(www.diabetestrialnet.org) for the pre-
vention of type 1 diabetes. TrialNet sys-
tematically evaluates therapies in new-
onset patients, as well as in pre-diabetic
subjects, and invites proposals from the
research community at large. The Im-
mune Tolerance Network (ITN) (www.
immunetolerance.org) is also accepting
applications to support therapies aimed
at tolerance induction and assays of
tolerance.
Although the secondary prevention
trials have failed to prevent or delay the
onset of diabetes thus far, a growing body
ofevidencesuggeststhatpreventionofdi-
abetic ketoacidosis (DKA) and hospital-
ization in newly diagnosed children is
possible and should be a major goal of
diabetescaresystems.TheDPT-1demon-
stratedthatDKAcanbepreventedbytest-
ing for islet autoantibodies and close
biochemical monitoring (13), and the Di-
abetes Autoimmunity Study in Youth
(DAISY) has conﬁrmed this observation
in the setting of an observational study
(35). Early diagnosis and treatment not
only eliminates mortality and greatly re-
ducesthecostofinitialtreatmentbutmay
also help preserve endogenous insulin se-
cretion and prevent acute and long-term
complications of the disease (20–22). In
the near future, we will likely see a resur-
gence of secondary prevention trials
translating the most successful ﬁndings
from tertiary prevention trials in patients
with established type 1 diabetes.
TERTIARY PREVENTION
AFTER DIAGNOSIS OF
DIABETES— In the past several
years, trials in patients with newly diag-
nosed type 1 diabetes became the main
focus of the research community. This
shift away from secondary to tertiary pre-
ventiontrialshasbeenpartiallyduetothe
ease of ﬁnding and retaining trial partici-
pants as well as the realization of how dif-
ﬁcult and expensive trials of the
magnitude of TRIGR, DIPP, ENDIT, or
DPT-1 are to perform. The goal is preser-
vation of remaining islet -cells to induce
and prolong partial remission. Unfortu-
nately, most islets have already been de-
stroyed by the time diabetes is diagnosed
(36). Autoimmune -cell destruction
continues after the diagnosis of diabetes.
A spontaneous temporary remission from
insulin dependency may occur in up to
27%ofpatients,soonafterdiagnosis(37),
and may be related to -cell rest caused
by insulin treatment (22). Younger age at
onset, male sex, high titer of islet autoan-
tibodies, severe DKA at diagnosis, and a
shortdurationofsymptomspriortodiag-
nosisareassociatedwithamorerapidloss
of C-peptide secretion (38). There are
conﬂicting reports concerning the effect
of the HLA-DR,DQ genotypes (37–39).
Residual -cell function can be retained
for decades after the onset of diabetes in a
subset of patients; however, for most pa-
tients very little normal function is re-
tained, -cell apoptosis continues, and
there is little spontaneous -cell regener-
ation (40). Complete spontaneous remis-
sion of type 1 diabetes is rare (41).
Arealisticoutcomeoftertiarypreven-
tion trials is prolongation of residual in-
sulin secretion, rather than complete
reversal of diabetes. Beneﬁts may include
simpler insulin regimen, lower A1C, and
reduced risk of hypoglycemia and micro-
vascularcomplications.Successisusually
measured by higher fasting and stimu-
latedC-peptidesecretioninthetreatment
versus placebo arm, with both groups of
patients maintaining good glycemic con-
trol. Preserved C-peptide is associated
with better glycemic control despite use
of less insulin. Lower insulin dose, lower
A1C, decreased glycemic variability, and
decreased incidence of hypoglycemia
have been used as secondary end points.
On behalf of the Immunology of Diabetes
Society, Greenbaum and Harrison (42)
have developed useful guidelines for in-
terventiontrialsinsubjectswithnewlydi-
agnosed type 1 diabetes.
Antigen-speciﬁc vaccines
Antigen-speciﬁc therapies are summa-
rized in Table 2. In the past couple of
years, perhaps the most exciting develop-
ment in the area of tolerance induction
hasbeenapparentefﬁcacyofDiamydvac-
cine based on the whole recombinant hu-
man GAD65 (rhGAD65) molecule
suspended in alum. Clinical trials in late-
onset autoimmune diabetes in adults
(LADA) (43,44) and adolescents with
newly diagnosed type 1 diabetes (45)
havesuggestedbeneﬁt.Inthelatterstudy,
patients receiving just two subcutaneous
injectionsofthevaccineexperiencedade-
cline in stimulated C-peptide secretion
approximately one-half that in the pla-
cebo group. Maximum stimulated C-
peptide at 15 months also decreased less
in the GAD-alum group compared with
the placebo group. The protective effect
was most pronounced in patients treated
within 3 months of diagnosis; these pa-
tients preserved their endogenous insulin
secretion over 15 months, in contrast to
the placebo group. The apparent bene-
ﬁcial effects were not explained by
changes in the GAD65 epitope pattern.
GAD65 autoantibody levels increased in
some patients; however, no serious side
effects were observed, and there has been
no evidence of the stiff person syndrome.
Treatment with GAD65 seemed to in-
duce a deviation of the GAD65-speciﬁc
T-cell response toward a protective im-
mune proﬁle. Three phase III trials of
the rhGAD65-alum vaccine are underway
in the U.S. and Europe (Table 2), and a
secondary prevention trial is under
consideration.
Insulin-related molecules continue to
attract great interest in vaccine develop-
ment.Analteredpeptideligandoftheim-
munodominant insulin peptide B:9-23
(NBI-6024; Neurocrine Biosciences)
completedphaseItrialswithasuggestion
of immunologic efﬁcacy (46) but was not
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(47).PhaseIstudieshavebeencompleted
orarenearingcompletionforaproinsulin
peptide 19-A3 (48), an insulin peptide
with incomplete Freund adjuvant and a
plasmid encoding proinsulin (Table 2).
TheDiaPep277peptideofHSP60has
been reported to preserve C-peptide in a
small trial of LADA patients with rela-
tively short follow-up (49). Phase II trials
in children showed no (50) or little (51)
effect. A large phase III trial is currently
enrolling patients in Europe and South
Africa (Table 2).
Systemic immunomodulators
Numerous non–antigen-speciﬁc immu-
nomodulators have been tried in newly
diagnosed patients. In early 2007, an ex-
cellent review by Staeva-Vieira, Peakman,
and von Herrath (52) summarized previ-
ously completed interventions, now
largely of historical value. Some interven-
tions, e.g., cyclosporine A, azatiopirine,
and anti-thymocyte globulin (ATG) plus
prednisolone, had unattractive side ef-
fects, including weakening of immunity
to infections, renal and pancreatic toxic-
ity, and potential long-term risk of malig-
nancies. Others, such as nicotinamide,
BCG vaccine, vitamin D supplementa-
tion, or elimination of dietary gluten,
while safer, have shown no efﬁcacy. Cy-
closporine A was efﬁcacious in prolong-
ing insulin production (53,54); however,
the treatment had to be continued for at
Table 3—Tertiary prevention trials of systemic immunomodulation after diagnosis of diabetes
Study (ref.) Drug/phase Sponsor/contact Age (years)
Time from diagnosis/
eligibility
TTEDD (89) Anti-CD3 (TRX4)/phase II TolerX Inc., JDRF/http://www.tolerrx.com
and clinicaltrials@tolerx.com
18–45 Any duration/C-peptide
detectable
DEFEND (59) Anti-CD3 (otelixizumab)/phase
III
TolerX Inc., JDRF/http://www.tolerrx.com
and defend@tolerx.com
18–35 12 weeks/C-peptide
0.2–3.5 pmol/ml
AbATE (90) Anti-CD3 (teplizumab)/phase II NIH, NIAID ITN/info@abatetrial.org 8–30 8 weeks
Delay (91) Anti-CD3 (teplizumab)/phase II NIH, NIDDK, JDRF/kevan.herold@yale.
edu
8–30 4–12 months/C-peptide*
0.2 pmol/ml
Protégé (92) Anti-CD3 (teplizumab)/phase II MacroGenics, Inc., JDRF/aknesel@mmgct.
com
8–35: 12–17†,
8–11†
12 weeks/C-peptide
detectable
TrialNet Rituximab
(93)
Anti-CD20 (rituximab)/phase II NIH, NIDDK, TrialNet, et
al./diabetestrialnet.org
8–45 12 weeks/C-peptide*
0.2 pmol/ml
START (94) ATG/phase II NIH, NIAID
ITN/info@type1diabetestrial.org
12–35 6 weeks/C-peptide*
0.4 pmol/ml
ATG (95,96) ATG/phase II Ministry of Health Czech
Republic/frsa@medicon.cz
15–35 6 weeks/C-peptide*
0.3 pmol/ml
TrialNet Abatacept
(97)
Anti–CTLA-4 NIH, NIDDK, TrialNet, et
al./diabetestrialnet.org
6–45 12 weeks/C-peptide*
0.2 pmol/ml
Interferon (62) hrIFN-	/phase II NIH, NIDDK/kr58q@nih.gov 3–25 6 weeks
Neulasta (98) Pegylated GCSF (pegﬁlgrastim)/
phase I/II
JDRF, University of
Florida/hallemj@peds.uﬂ.edu
12–45 6 months/C-peptide
0.2 pmol/ml
Anakinra (99) IL-1r antagonist (anakinra)/
phase I/II
University of Texas Southwestern Med
Center/Soumya Adhikarti, MD
6–18 1 week
AIDA (100) IL-1r antagonist (anakinra)/
phase II/III
JDRF, Steno Diabetes Center, Oeresund
Diabetes Academy/tmpo@steno.dk
18–35 12 weeks/C-peptide*
0.2 pmol/ml
Etanercept (61) TNF-	 inhibitor (etanercept)/
phase I/II
University of Buffalo, Immunex, Amgen/
tquattrin@upa.chob.edu
7–18 4 weeks/positive islet
autoantibody
Cord blood (63) Autologous umbilical cord
blood transfusion/phase I/II
JDRF, NIH, University of
Florida/hallemj@peds.uﬂ.edu
1 Autologous cord blood
stored
Prochymal (101) Adult human mesenchymal
stem cells/phase II
Osiris Therapeutics, JDRF/osiris@osiris.
com
18–30 2–16 weeks/C-peptide
detectable
AdiStem (102) Autologous adipose-derived
stem cells/phase I/II
AdiStem Ltd./lettielucero@yahoo.com 16–60 2 years
Dendritic cells (68) Autologous dendritic
cells/phase I
NIH, NIDDK, University of Pittsburgh/
brian.copeman@chp.edu
18–35 5 years
MMTT C-peptide  area under the curve for C-peptide in response to a 2-h mixed meal tolerance test. *Stimulated. †Pending approval by data monitoring
committee. AbATE, Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes; AIDA, Anti–Interleukin-1 in Diabetes Action; ATG,
anti–T-cell globulin; AUC, area under the curve; IFN, interferon; GCSF, granulocyte colony–stimulating factor; MMTT, mixed-meal tolerance test; NIAID ITN,
National Institute of Allergy and Infectious Diseases Immune Tolerance Network; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH,
National Institutes of Health; PBMC, peripheral blood mononuclear cell; JDRF, Juvenile Diabetes Research Foundation; START, Study of Thymoglobulin to Arrest
Newly Diagnosed Type 1 Diabetes; TNF-	, tumor necrosis factor-	; TTEDD, TRX4 Monoclonal Antibody in Type 1 Diabetes.
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the effect was lost when the drug was
discontinued. In addition, the patients
would progress to insulin dependency
within 3 years, even if treatment was con-
tinuedandC-peptidesecretionwasmain-
tained (55). Renal and pancreatic -cell
toxicityaswellasthecostsofthedrugand
the monitoring of its levels in the blood
led to a consensus that the risks outweigh
the beneﬁts. Nevertheless, cyclosporine
trials provided a proof of principle that
immunosupression can slow the destruc-
tionofthe-cells,evenifitcannotstopit.
The trials also showed that the effect of
immunosupression was greatest if the in-
tervention was started within 6 weeks of
diabetes diagnosis, suggesting that -cell
mass at the initiation of immunotherapy
maybyakeypredictorofsuccess.Table3
summarizes currently registered trials.
Monoclonal anti-CD3 antibody.
Monoclonalanti-CD3antibodytreatment
hasreceivedalotofattention.Theantibody
transiently activates the CD3 receptor,
causes cytokine release, and ultimately
blocks T-cell proliferation and differenti-
ation; the longer-term beneﬁts may be
due to the induction of regulatory T-cells.
Humanized Ortho-Kung T-cell antibody
hOKT3
1(Ala-Ala) or CHAglyCD3 anti-
CD3 monoclonals, engineered to abro-
gate complement Fc binding, do not
induce severe cytokine release syn-
dromes, in contrast to the standard
OKT3, but have been associated with fe-
ver, rash, and in some patients adenopa-
thy, depending upon the dose (56).
Reactivation of Epstein-Barr virus infec-
tion observed in some patients appears to
be self-limiting with a single course of
therapy (57). Two randomized, placebo-
controlled phase I/II trials with hOKT3
have suggested slower decline in stimu-
lated C-peptide, lower A1C levels, and
lower insulin requirements in patients re-
ceiving hOKT3 compared with placebo
(56,57). The C-peptide levels held for at
least 12 months, especially in patients
withhigherbaselineC-peptidelevels,fol-
lowed by a recurrence of progressive loss
of C-peptide. Signiﬁcant but smaller ben-
eﬁts in C-peptide levels persist up to 4
years after treatment with a single course
Table 3—Continued
Route Dosing Treated:placebo
Follow-up duration/primary
end point Status/target size
i.v. 8 daily injections All:0 4 years/deﬁne highest tolerated
dose
Enrolling/n  100
i.v. 8 daily injections 2:1 2 years/MMTT C-peptide Enrolling/n  240
i.v. 14 daily injections/escalation dose;
2nd course after 12 months
2:1/open label 2 years/MMTT C-peptide (4-h
AUC)
Enrolling/n  81
i.v. 14 daily injections/escalation dose;
2nd course after 12 months
1:1 1 year/MMTT C-peptide (4-h
AUC)
Enrolling/n  60
i.v. 14 daily injections/2nd course
after 6 months
3:1 2 years/insulin dose  A1C
MMTT C-peptide
Enrolling/n  530
i.v. 4 weekly injections of 375 mg/m
2
each
2:1 2 years/MMTT C-peptide Enrollment closed/
n  87
i.v. 4 daily injections/escalation dose 2:1 2 years/MMTT C-peptide Enrolling/n  66
i.v. 4 daily injections 1:1 3 years/C-peptide Enrollment closed/
n  28
i.v. 10 mg/kg monthly injections for 2
years (27 doses)
2:1 2  2 years/MMTT C-peptide Enrollment closed/
n  111
p.o. 5,000 or 30,000 units once daily
for 1 year
2:1 1 year/MMTT C-peptide Enrollment closed/
n  81
s.c. 6 mg weekly for 12 weeks 1:1 2 years/adverse events, MMTT
C-peptide
Enrolling/n  21
s.c Daily for 28 days Open label Change in EGR2 expression by
PBMC, C-peptide
Enrolling/n  15
s.c. 100 mg once daily for 2 years 1:1? 2 years/adverse events, MMTT
C-peptide
Enrolling/n  160
s.c. 0.4 mg/kg up to 25 mg twice
weekly for 24 weeks
1:1 24 weeks/change in A1C,
MMTT C-peptide
Enrollment closed/
n  18
i.v. One infusion Open label 2 years/MMTT C-peptide,
A1C, insulin dose
Enrolling/n  23
i.v. Infusion once per month for 3
months
1:1? 2 years/MMTT C-peptide Enrolling/n  60
i.v. One infusion Open label Insulin dependence/insulin
dose
Enrolling/n  30
i.d. Intradermal injection of cells
treated ex vivo with antisense
oligonucleotides
1:1 Adverse events Enrolling/n  15
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effects, this therapy will likely require re-
peated administration of the drug, which
isbeingtestedinseveraltrials(Table3)or
in combination with another therapeutic
agent. While the short-term follow-up re-
sults are encouraging, anti-CD3 therapy
represents one of the more aggressive ap-
proaches to tertiary prevention of type 1
diabetes today, with a signiﬁcant burden
on patients. The typical protocol includes
2–3 screening visits, 8–12 outpatient vis-
its on consecutive days, where patients
mayspend4heachdayundergoingtreat-
ment and observation, and about 10 ad-
ditionalvisitsduringthe2-yearfollow-up
(59). With two dosing cycles 6–12
months apart, the number of visits in-
creasesto30–40duringtheinitial2years
postdiagnosis, clearly more than the
8–10 visits for insulin therapy required
by current clinical standards of care.
Rituximab. Rituximab is a monoclo-
nal antibody that targets the CD20 recep-
tor unique to B-cells. Rituximab inhibits
the B-cell function, thus reducing presen-
tation of autoantigen to T-cells and theo-
retically secondarily preventing B-cell
expansionandisletautoantibodyproduc-
tion. This medication is approved for the
treatment of non-Hodgkin’s lymphoma
and has shown success in treatment of
patients with rheumatoid arthritis. Trial-
Net has completed a phase II trial includ-
ing 4 weekly injections of rituximab
(Table 3), and the results were presented
at the American Diabetes Association’s
Scientiﬁc Sessions in June 2009. Newly
diagnosed patients with type 1 diabetes
(age 8–40 years) treated with rituximab
had higher C-peptide 2-h area under the
curve after a mixed meal and lower A1C
and insulin doses compared with the pla-
cebo group. The full results of this trial
should be available shortly.
Anti–CTLA-4 Ig. A trial of monthly
infusions of anti–CTLA-4 Ig (abatacept)
over a 2-year period has ﬁnished recruit-
ment, and the results from TrialNet
should be available in 2011. A high-
afﬁnity variant of CTLA-4 Ig (LEA29Y,
belatacept) has been tested in islet trans-
plantation studies and may be next in
line.
Antithymocyte globulin. Antithy-
mocyte globulin (ATG) has been used in
organ transplantation but has not yet
been shown to be effective in inducing
immune tolerance. ATG is produced by
taking human thymus cells and injecting
them into an animal such as a rabbit or
horse. The animal makes multiple anti-
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marily but not only T-cell in origin, and
then they are puriﬁed to ATG. Injected
back into the subject, ATG binds to T-
cells and other immune cells, causing the
host to see these as foreign because of the
attached antibodies and eliminate them.
A small clinical trial previously showed a
reduction of A1C levels and lower insulin
requirements (60). However, two pa-
tients developed severe thrombocytope-
nia. A European trial has recently been
completed using a newer form of ATG,
and a phase II trial of ATG through the
ITN is enrolling type 1 diabetic patients
(Table 3).
Tumor necrosis factor-, IL-1 re-
ceptor antagonist, pegylated granulo-
cyte colony–stimulating factor, and
human recombinant interferon-. A
number of agents previously proven ef-
fective in other autoimmune diseases are
being evaluated in phase I/II tertiary pre-
vention trails of type 1 diabetes (Table 3).
Tumor necrosis factor-	 (TNF-	) inhibi-
tor (etanercept) has been previously used
in treatment of arthritis and Crohn’s dis-
ease. A small pilot study has found in-
creased C-peptide area under the curve
andlowerA1Candinsulindosesintype1
diabetic patients after 24 weeks of etaner-
cept therapy started not more than 4
weeks after diagnosis (61). Trials of IL-1
receptor antagonist (IL-1ra) (anakinra)
approvedforrheumatoidarthritisandpe-
gylated granulocyte colony–stimulating
factor (GCSF) (pegﬁlgrasim) used for
neutropenia are enrolling participants.
Theseagentsareadministeredsubcutane-
ously. Oral human recombinant interfer-
on-	 (hrINF-	) has been found safe in
doses of 5,000 and 30,000 units/day but
slowed C-peptide loss only in the 5,000
units/dayarm,aﬁndingthatrequiresrep-
lication (62).
Regulatory T-cells. Cell therapy tar-
geting regulatory T-cells (Tregs) in vivo
using certain drugs can be potentially
hazardous, resulting in signiﬁcant side ef-
fects and “off-target” effects. Therefore,
novel approaches to isolate and expand
polyclonal and antigen-speciﬁc Tregs in
vitro have been developed for immuno-
therapy. While the efﬁcacy of Treg trans-
fer is well established in animal models,
clinical trials in new-onset type 1 diabetic
patients have just begun (Table 3). Um-
bilical cord blood may contain higher
numbers of functional populations of
Tregs. An open-label trial of autologous
cord blood transfusion in children with
newlydiagnosedtype1diabetesisunder-
way (63). In the future, cord blood may
turn out to be a reliable source of pluri-
potenthematopoeticstemcellsapplicable
to trials of islet regeneration. Two trials of
adult stem cell infusions are registered in
the clinicaltrials.gov database (Table 3),
and more are likely to be added in the
near future. Autologous stem cell trans-
plantation, particularly from bone mar-
row, has been successfully used in cancer
patients and is intensively discussed as a
treatment option for autoimmune dis-
orders. Autologous nonmyeloablative
hematopoietic stem cell transplanta-
tion, with concomitant high-dose im-
munosuppression, has been reported in
new-onsettype1diabetes(64,65).Dur-
ing a mean follow-up of 19 months, 14
of 15 patients became insulin free, their
-cell function increased signiﬁcantly,
their anti-GAD antibody levels de-
creased, and their A1C levels were
maintained at 7%. A longer follow-up
(30 months) has suggested increased C-
peptide levels in some of these patients
(66). Nevertheless, nearly all patients
suffered from transplantation-related
complications, which may compromise
the application of this approach to type
1 diabetes. Trials to replicate this report
have been registered in several coun-
tries (67).
Dendritic cells. Cell therapy using-
dendritic cells is based on the hypothe-
Table 5—Tertiary prevention trials of combination immunotherapy after diagnosis of diabetes
Study (ref.) Drug/phase Sponsor/contact
Age
(years)
Time from diagnosis/
eligibility
TrialNet MMF/DZB
(107)
Mycophenolate mofetil &
daclizumab/phase III
NIH, NIDDK, TrialNet/diabetestrialnet.org 8–45 12 weeks/C-peptide*
0.2 pmol/ml
03-DK-0245 (108) exenatide & daclizumab/phase II NIH, NIDDK, Amylin Pharmaceuticals/
1-800-411-1222 (Amylin),
prpl@mail.cc.nih.gov
18–60 5 years/C-peptide*
0.3–1.2 ng/ml
Proleukin  rapamune
(109)
hrIL-2 (aldesleukin) & sirolimus/
phase I
NIH, NIAID
ITN/diabetes@benaroyaresearch.org
18–45 3–48 months
09-DK-0056 (75) Sitagliptin/lansoprazole rhGAD65
(Diamyd)/phase II
NIH, NIDDK, Diamyd Therapeutics/
1-800-411-1222 (Diamyd),
prpl@mail.cc.nih.gov,
davidmh@intra.niddk.nih.gov
16–30 4 months/C-peptide
0.2 pmol/ml
E1-INT (110) EGF and gastrin/phase II Transition therapeutics/Aleksandra
Pastrak, MD
18–40 1 year
Sao Paulo (64,65) Autologous stem cell transplantation
and cyclophosphamide  rabbit
ATG/phase II
University of Sao Paulo, Northwestern
University,
Genzyme/jvoltar@fmrp.usp.br
14–31 6 weeks
Shanghai (67) Autologous stem cell transplantation
and cyclophosphamide  rabbit
ATG/phase II
Shanghai JiaoTong
University/guangning@medmail.com.cn
14–35 6 months
*Stimulated. ATG, anti–T-cell globulin; DZB, daclizumab; EGF, epidermal growth factor; MMF, mycophenolate mofetil; NIAID ITN, National Institute of Allergy
and Infectious Diseases Immune Tolerance Network.
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can be modiﬁed to favor a protective
phenotype rather than one favoring dis-
ease development. These strategies use-
“immature” dendritic cells that are in
vitroderivedfrommonocyteprecursors
isolated from diabetic subjects and then
either modiﬁed with siRNA or an insu-
lin peptide and then reinjected into the
same individuals with the hope of reset-
ting the immune response to islet anti-
gens. One protocol is completing phase
I safety studies (68), and the other is
about to begin this year.
Islet regeneration
This topic has been recently covered by
excellent reviews (e.g., 69) and is beyond
the focus of the current article. However,
we list current clinical trials of monother-
aphy (Table 4) or combination therapy
(Table 5) that include exenatide, sita-
glipin, islet neogenesis–associated pro-
tein (INGAP) peptide, and pioglitazone.
ThepromisingE1-I.N.T.trial,acombina-
tion therapy containing gastrin and epi-
dermal growth factor, will be followed by
a trial of proton pump inhibitor to ele-
vated gastrin levels combined with a glu-
cagon-like peptide analog in one arm and
further combined with GAD in another
arm and will be starting soon.
Metabolic control and -cell rest
Weight loss and increased physical activ-
ity (70) can neutralize the powerful effect
of insulin resistance on progression to
type1diabetes(71,72).Meticulousblood
glucosecontrolafterdiabetesonsetresult-
ing in -cell rest is also believed to help
preserve residual insulin secretion (73),
and the TrialNet Metabolic Control Trial
(74) is about to test this hypothesis.
Combination treatments
Many in the ﬁeld of immunotherapy to-
day feel that combination therapies may
enhance efﬁcacy while lowering risk and
predict that one day multidrug immuno-
therapy will become the standard of care
for newly diagnosed type 1 diabetes. Al-
though combination treatments may be
more likely to increase the risk of adverse
events if chosen within the same thera-
peutic family, using therapies fromdiffer-
ent treatment pathways may reduce these
risks. Current trials of combination im-
munotherapy are summarized in Table 5.
Initial systemic immunosuppression fol-
lowed by antigen-speciﬁc induction of
toleranceorisletregenerationseemstobe
a logical approach and is about to be
tested by a recently opened National In-
stitute of Diabetes and Digestive and Kid-
ney Diseases trial (108).
CONCLUSIONS AND A
LOOK INTO THE FUTURE—D e -
velopment of safe and effective preven-
tion of type 1 diabetes is a major public
health goal in industrialized countries to-
day, as evidenced by strong legislative
supportintheU.S.intheformoftheSpe-
cial Statutory Funding Program (http://
www.t1diabetes.nih.gov). While hundreds
of preventive modalities have succeeded
in animal models of type 1 diabetes
(76,77), prevention of human type 1 dia-
betesremainselusiveasofearly2009.Ge-
netic and environmental factors that
determine the relapsing-remitting course
of -cell destruction, culminating in full
insulin dependence, are being discov-
ered. In the long run, primary prevention
of islet autoimmunity will likely be the
optimal approach to the prevention of
type 1 diabetes, especially in high-risk
groups, such as ﬁrst-degree relatives.
However, environmental triggers of islet
autoimmunity need to be better deﬁned.
Poor predictive value of the existing ge-
netic screening tools also means that the
number of children needing intervention
willremainhighinrelationtothenumber
of type 1 diabetes cases prevented. If a
primary prevention is not feasible in the
general population, mass screening for is-
let autoantibodies and secondary preven-
tion may be the next option.
Table 5—Continued
Route Dosing
Treated:
placebo
Follow-up duration/primary
end point Status/target size
MMF p.o., DZB i.v. MMF twice daily 600 mg/m
2 for 2 years,
DZB twice in 2 weeks 1 mg/kg up to
100 mg
2:1 4 years/MMTT C-peptide Enrollment closed/
n  126
Exendin-4 s.c., DZB i.v. 2  2 factorial 20 weeks Enrollment closed/
n  16
hrIL-2 s.c., sirolimus
p.o.
hrIL-2 4.5  10
6 IU/day three times
weekly for 4 weeks, sirolimus
escalating dose for 12 weeks
Open label 2 years/adverse events MMTT
C-peptide
Enrolling/n  10
Sitagliptin p.o.,
rhGAD65 s.c.
MMTT C-peptide Enrolling/n  164
s.c. Daily for 4 weeks 3:1 6 months/Arg-stimulated C-
peptide
Enrollment closed/
n  20
i.v. Cyclophosphamide 200 mg/kg, rabbit
ATG 4.5 mg/kg
Open label 3 years/adverse events,
insulin dose
Published/n  20
i.v. Cyclophosphamide 200 mg/kg, rabbit
ATG 4.5 mg/kg
Open label 3 years/insulin dose Enrolling/n  30
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body is present, most individuals pro-
gress to diabetes in 5–10 years. The pres-
ence of more than one islet autoantibody,
combined with susceptibility HLA-
DR,DQ and protein tyrosine phosphatase
N22 (PTPN22) genotypes (78), helps to
identify individuals with sufﬁciently high
risk of disease to attempt prevention.
However, these screening tools need fur-
ther improvement to exclude individuals,
particularly adults, with loss of -cells so
slow that overt diabetes will not occur
during the person’s lifetime. Further-
more, prediction algorithms need to be
sharpened before being applied to the
general population, where the majority of
type 1 diabetes cases occur, yet the pre-
dictive value of genetic markers is lower
than among relatives.
As patients develop autoimmunity,
-cell function declines and so does the
potential therapeutic beneﬁt of interven-
tion. Additionally, once the autoimmune
process has begun it might become pro-
gressively more difﬁcult to alter, as sug-
gested by animal models where antigen-
speciﬁc therapies used prior to the onset
of disease can be far more effective than
the same treatments given at the time of
disease onset. In retrospect, the DPT-1
and ENDIT trials seem somewhat specu-
lative when viewed in the more complete
context of the complexity of immuno-
regulation and autoimmunity we have
now deﬁned. It is something to keep in
mind while extrapolating to pre-diabetes,
the promising ﬁndings from prevention
trials in patients with established type 1
diabetes.
Technological advantages of insulin
pumps and continuous glucose monitor-
inginﬂuenceperceivedbeneﬁtsofimmu-
notherapy after diagnosis of diabetes.
Multiple logistic issues remain, e.g., the
anticipated duration, toxicity, and com-
plexity of immunotherapy. Unless toler-
ance can be established or restored
permanently in a limited time period, in-
tervention may need to be life-long akin
to gluten-free diet for celiac disease. It is
currently impossible to compare the cost-
to-beneﬁt ratio of such efforts with those
of the established and emerging insulin
treatment regimens. It is, however, im-
portant to keep in mind that insulin ther-
apy, while not easy or complication free,
has led to a dramatic improvement of the
mortality and morbidity associated with
type 1 diabetes over the past 20–30 years
(79–81).
Although more targeted antibody
therapies are being used, these agents are
still relatively nonspeciﬁc and potentially
toxic to some trial participants. Currently
used systemic immunomodulators may
carry a risk of long-term complications
that is unacceptable for type 1 diabetes
prevention. However, this work is impor-
tantbecauseevenwithsuccessfulprimary
or secondary prevention programs there
will always be patients who develop clin-
ical type 1 diabetes.
Diabetes prevention research is ex-
panding at an unprecedented rate. The
history of diabetes is ﬁlled with many
groundbreaking discoveries. If the past
performance does predict future returns,
the prevention of type 1 diabetes has a
bright future.
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